Track topics on Twitter Track topics that are important to you
Allocation: Non-Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Group B Streptococcus (GBS) Disease
Group B streptococcus (GBS) vaccine
Institute for Pharmacokinetic and Analytical Studies
Via Mastri, 36
CH - 6853 Ligornetto
Enrolling by invitation
Published on BioPortfolio: 2014-08-27T03:16:32-0400
This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.
This study looks at the body's immune response to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P2 study. Blood will be drawn and evaluated for GBS antibody leve...
Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus. Part B: To evaluate the long term safety profile of the GBS-...
The study investigated the immune response induced by the Group B streptococcus vaccine in healthy pregnant women. In addition, the study investigated the amount of vaccine induced antibod...
The study is aimed at assessing pharyngeal and nasopharyngeal Streptococcus pneumonia carriage and pharyngeal Group A streptococcus carriage among field units new recruits.
Recent findings have open new perspectives on group A Streptococcus (GAS) virulence understanding with special focus on the carrier stage and new hopes for an efficient vaccine against this important ...
Group A streptococcus (GAS) is a serious human pathogen that affects people of different ages and socio-economic levels. Although vaccination is potentially one of the most effective methods to contro...
Vaccination in pregnancy has been shown to be effective for the prevention of influenza and pertussis in infants, providing support for similar strategies to prevent group B streptococcus and respirat...
Current predominant routes of group B Streptococcus (GBS) transmission in preterm neonates admitted to neonatal intensive care unit (NICU) are poorly defined. We report two overlapping clusters of GBS...
Antigenic diversity of the M protein is a major constraint to the development of immunity to group A streptococcus (GAS). We demonstrate that a conserved cryptic epitope that is unrecognized by the ho...
A large heterogeneous group of mostly alpha-hemolytic streptococci. They colonize the respiratory tract at birth and generally have a low degree of pathogenicity. This group of species includes STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS SANGUIS; STREPTOCOCCUS SOBRINUS; and the STREPTOCOCCUS MILLERI GROUP. The latter are often beta-hemolytic and commonly produce invasive pyogenic infections including brain and abdominal abscesses.
A species of gram-positive bacteria in the STREPTOCOCCUS MILLERI GROUP. It is the most frequently seen isolate of that group, has a proclivity for abscess formation, and is most often isolated from the blood, gastrointestinal, and urogenital tract.
A species of Streptococcus that is pathogenic in fish and may also cause disease in humans who routinely handle infected fish. Those who are of Asian descent, elderly, or have chronic diseases such as DIABETES MELLITUS; RHEUMATIC HEART DISEASE; or LIVER CIRRHOSIS are more susceptible to Streptococcus iniae infections.
A species of gram-positive bacteria in the STREPTOCOCCUS MILLERI GROUP. It is commonly found in the oropharnyx flora and has a proclivity for abscess formation in the upper body and respiratory tract.
A species of gram-positive bacteria in the STREPTOCOCCUS MILLERI GROUP. It is commonly found in the oropharynx flora and has a proclivity for abscess formation, most characteristically in the CENTRAL NERVOUS SYSTEM and LIVER.
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...